Table 4 Univariate analysis of potential prognostic factors for overall Survival (n = 35 patients) following primary tumor resection and liver directed therapy (LDT) , respectively

Gender

 Male

24

42 (21–98)

0.7

96 (34–130)

0.4

 Female

11

37 (12–68)

62 (63–126)

Targeted therapy

 TKI+

16

98 (57–133)

0.032

151 (126–202)

0.003

 TKI−

19

40 (12–64)

61 (25–103)

ECOG

 0

29

57 (37–98)

0.001

103 (79–151)

<0.001

 > 1

6

12 (9–18)

15 (13–34)

Age

 < 65 years

18

64 (35–98)

0.07

96 (34–151)

0.31

 > 65 years

17

40 (12–57)

63 (79–126)

Tumor distribution

 unilobular

28

98 (21–76)

0.911

126 (25–151)

0.8

 multilobular

7

42 (12–98)

86 (54–126)

Synchronous Extrahepatic Disease

 Yes

7

21 (9–37)

0.312

63 (54–126)

0.727

 No

28

47 (28–98)

86 (61–159)

Liver metastasis Timing

 Synchronous

6

9 (8–12)

0.006

15 (8–63)

0.006

 Metachronous

29

47 (28–98)

96 (54–151)

Tumor size, cm

 < 45 mm

21

98 (28–133)

0.007

103 (86–151)

0.007

 > 45 mm

14

37 (12–57)

63 (18–85)

Resection margin

 Radical resection (R0)

30

47 (21–98)

0.013

96 (48–151)

0.041

 Irradical resection (R1/R2)

5

9 (8–28)

86 (13–92)

Number of metastases

 Solitary

22

64 (12–98)

0.850

85 (54–153)

0.990

 Multiple

13

42 (21–76)

116 (34–130)

T-stage

 T1/T2

16

47 (37–98)

0.062

126 (62–151)

0.257

 T3/T4

19

40 (12–64)

85 (54–103)

Grading of RCC

 Low (G1/G2)

24

47 (37–133)

0.543

116 (63–126)

0.501

 High (G3/G4)

11

28 (9–98)

85 (51–151)

Disease-free intervall

 < 12 months

17

13 (9–42)

0.002

79 (18–96)

0.2

 > 12 months

18

64 (42–98)

103 (62–151)

Histology

 Clear cell

25

47 (40–98)

0.821

96 (51–151)

0.498

 Non clear cell

10

42 (18–132)

85 (54–116)

Surgical complications

 Yes

10

28 (21–40)

0.996

85 (49–118)

0.104

 No

25

47 (13–98)

151 (54–202)